BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) still has a relatively high complication rate, underscoring the importance of high-quality training. Despite existing guidelines, real-world data on training conditions remain limited. This pan-European survey aims to systematically explore the perceptions surrounding ERCP training. METHODS: A survey was distributed through the friends of United European Gastroenterology (UEG) Young Talent Group network to physicians working in a UEG member or associated states who regularly performed ERCPs. RESULTS: Of 1035 respondents from 35 countries, 649 were eligible for analysis: 228 trainees, 225 trainers, and 196 individuals who regularly performed ERCP but were neither trainees nor trainers. The mean age was 43 years, with 72.1% identifying as male, 27.6% as female, and 0.3% as non-binary. The majority (80.1%) agreed that a structured training regimen is desirable. However, only 13.7% of trainees and 28.4% of trainers reported having such a structured program in their institutions. Most respondents (79.7%) supported the concept of concentrating training in centers meeting specific quality metrics, with 64.1% suggesting a threshold of 200 annual ERCPs as a prerequisite. This threshold revealed that 36.4% of trainees pursued training in lower-volume centers performing <200 ERCPs annually. As many as 70.1% of trainees performed <50 annual ERCPs, whereas only 5.0% of trainers performed <50 ERCPs annually. A low individual trainee caseload (<50 ERCPs annually) was more common in lower-volume centers than in higher-volume centers (82.9% vs. 63.4%). CONCLUSIONS: The first pan-European survey investigating ERCP training conditions reveals strong support for structured training and the concentration of training efforts within centers meeting specific quality metrics. Furthermore, this survey exposes the low availability of structured training programs with many trainees practicing at lower-volume centers and 71% of all trainees having little hands-on exposure. These data should motivate to standardize ERCP training conditions further and ultimately improve patient care throughout Europe.
- MeSH
- cholangiopankreatografie endoskopická retrográdní * normy škodlivé účinky MeSH
- dospělí MeSH
- gastroenterologie * výchova MeSH
- klinické kompetence normy MeSH
- lidé středního věku MeSH
- lidé MeSH
- průzkumy a dotazníky statistika a číselné údaje MeSH
- studium lékařství specializační postgraduální * normy metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
INTRODUCTION: The objective of this study was to assess the impact of the Enhanced Recovery After Surgery (ERAS) programme implementation on treatment costs at a university-type centre, using the DRG scheme. MATERIALS AND METHODS: Retrospective analysis of patients' data in a group of 604 individuals enroled in the study. We evaluated three groups of patients according to the ERAS clinical protocol (CP): (1) CP oncogynaecology, (2) CP simple hysterectomy, (3) CP laparoscopy. The study aimed to evaluate the impact on the length of stay (LOS), savings in bed-days, and the reduction in direct treatment costs. Three parameters-antibiotic consumption, blood derivative consumption and laboratory test costs-were chosen to compare direct treatment costs. The statistical significance of the difference in the observed parameters was tested by a two-sample unpaired t test with unequal variances at the 0.05 significance level. RESULTS: We analysed data from 604 patients. In all three groups, the length of stay (LOS) was significantly reduced. The most significant reduction was observed in the CP oncogynaecology group, where the LOS was reduced from 11.1 days to 6.8 days (2022) and 7.6 days (2023) compared to 2019 (p < 0.05). Furthermore, there was a notable reduction in inpatient bed-days, which resulted in the capacity being made available to admit additional patients. A statistically significant reduction in direct costs was observed in the group of CP hysterectomy (antibiotic use) and in the CP laparoscopy (laboratory test costs). CONCLUSIONS: The implementation of the ERAS principles resulted in a number of significant positive economic impacts-reduction in the LOS and a corresponding increase in bed capacity for new patients. Additionally, direct treatment costs, including those related to antibiotic use or laboratory testing were reduced. The Czech Republic's acute healthcare system, like the majority of European healthcare systems, is financed by the DRG system. This flat-rate payment per patient encourages hospital management to seek cost-reduction strategies. The results of our study indicate that fast-track protocols represent a potential viable approach to reducing the cost of treatment while simultaneously meeting the recommendations of evidence-based medicine.
- MeSH
- délka pobytu statistika a číselné údaje ekonomika MeSH
- dospělí MeSH
- gynekologické chirurgické výkony * ekonomika MeSH
- hysterektomie ekonomika MeSH
- klasifikační systém DRG MeSH
- laparoskopie ekonomika MeSH
- lidé středního věku MeSH
- lidé MeSH
- náklady na zdravotní péči * statistika a číselné údaje MeSH
- retrospektivní studie MeSH
- senioři MeSH
- urychlená pooperační rehabilitace * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Mucosal visualization during upper gastrointestinal (UGI) endoscopy can be impaired by the presence of foam, bubbles, and mucus. Some UGI endoscopy visibility scales have been proposed but have not undergone multicenter validation. This study aimed to develop and validate the Gastroscopy RAte of Cleanliness Evaluation (GRACE) scale. METHODS: A multicenter, international, cross-sectional study was conducted. The GRACE scale is based on a score from 0 (worst) to 3 (excellent) for esophagus, stomach, and duodenum, for a total ranging from 0 to 9. In phase 1, four expert endoscopists evaluated 60 images twice, with a 2-week interval between rounds; in phase 2, the same 60 images were scored twice by one expert and one nonexpert endoscopist from 27 endoscopy departments worldwide. For reproducibility assessment and real-time validation, the scale was applied to consecutive patients undergoing gastroscopy at each center. RESULTS: On internal validation, interobserver agreement was 0.81 (95 %CI 0.73-0.87) and 0.80 (95 %CI 0.72-0.86), with reliability of 0.73 (95 %CI 0.63-0.82) and 0.72 (95 %CI 0.63-0.81), in the two rounds, respectively. On external validation, overall interobserver agreement was 0.85 (95 %CI 0.82-0.88) and reliability was 0.79 (95 %CI 0.73-0.84). In real-time evaluation, the overall proportion of correct classifications was 0.80 (95 %CI 0.77-0.82). CONCLUSIONS: The GRACE scale showed good interobserver agreement, reliability, and validity. The widespread use of this scale could enhance quality and standardize the assessment of mucosal cleanliness during UGI endoscopy, pushing endoscopists to strive for excellent visibility and reducing the risk of missed lesions.
- MeSH
- dospělí MeSH
- duodenum MeSH
- gastroskopie * metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- odchylka pozorovatele * MeSH
- průřezové studie MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- žaludeční sliznice MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- validační studie MeSH
BACKGROUND AND AIMS: Peroral endoscopic myotomy (POEM) is an established treatment for achalasia with compelling midterm efficacy. In this study, we analyzed the long-term efficacy, sought predictors of failure, and comprehensively assessed post-POEM reflux. METHODS: We performed a retrospective analysis of a prospective database of patients undergoing POEM at a high-volume center from December 2012 to June 2023. Patients who had completed a 3-month follow-up were included. Efficacy was assessed at 3, 6, and 8 years using the Eckardt score (ES). An ES ≤2 was considered treatment success. At 3 months, gastroscopy, manometry, 24-hour pH monitoring, and fluoroscopy were performed, and gastroscopy was repeated at 2 and 3 years. At each visit, patients were assessed for reflux symptoms and quality of life. RESULTS: From 496 included patients, 3-, 6-, and 8-year follow-ups were completed in 302, 115, and 40 patients, respectively. The treatment success rates at 3, 6, and 8 years according to the Kaplan-Meier analysis were 90.2% (95% confidence interval [CI], 87.2-93.3), 82.3% (95% CI, 77.3-87.6), and 73.5% (95% CI, 64.8-83.5), respectively. Year of procedure was the only predictor of outcome. Fifty-three patients (10.7%) encountered failure or recurrence. Treatment success of redo-POEM (n = 20) at 1 year was significantly lower (62.9% [95% CI, 44.3-89.2] vs 96.9% [95% CI, 95.3-98.5], P < .001). At 3 months, 40.4% of patients had reflux esophagitis (RE), 43.6% of patients had an acid exposure time >4.5%, 39.2% of patients were using proton pump inhibitors (PPIs), but only 24.2% had reflux symptoms. At 2 to 3 years, 50.8% of patients took PPIs, whereas 39.6% were symptomatic. RE decreased to 20.2% at 6 years. CONCLUSIONS: The treatment success of POEM declines over time but remains sufficiently high in the long term. Experience with the procedure improves the outcome. Gastroesophageal reflux affects almost half of patients early after POEM and decreases substantially over time together with a rise in PPI use.
- MeSH
- achalázie jícnu * chirurgie patofyziologie MeSH
- časové faktory MeSH
- centra terciární péče MeSH
- dolní jícnový svěrač * chirurgie MeSH
- dospělí MeSH
- endoskopické operace přirozenými otvory * metody MeSH
- fluoroskopie MeSH
- gastroezofageální reflux * etiologie epidemiologie MeSH
- gastroskopie MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- manometrie MeSH
- monitorování jícnového pH MeSH
- následné studie MeSH
- pooperační komplikace * epidemiologie MeSH
- pyloromyotomie * metody MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND AND AIMS: Gastric restriction techniques have recently emerged as minimally invasive bariatric procedures. Endoscopic sutured gastroplasty (ESG) with the Endomina (Endo Tools Therapeutics, Gosselies, Belgium) triangulation platform proved to be safe and effective for the treatment of class I and II obesity in prospective studies. In this registry, we aimed to further assess on a larger scale the safety and efficacy of the procedure in routine practice with a dedicated device. METHODS: This was a multicenter, observational, prospective post-market study including patients with obesity undergoing Endomina ESG. The primary safety outcome was the occurrence of serious adverse device effects (SADEs) at 12 months. The primary efficacy outcome was the technical success defined by completing the procedure without premature abortion owing to technical issues. The rates of procedure-related adverse events, weight loss outcomes, and quality of life changes were collected. RESULTS: A total of 142 patients underwent ESG in 3 centers from July 2020 to March 2023. Of these, 67 (mean body mass index, 38.5 ± 6.3 kg/m2) reached at least 12 months of follow-up up to October 2022. Technical success was 100%. No SADEs occurred. Seven mild procedure-related adverse events were reported overall. Mean percentage of excess weight loss and total body weight loss at 12 months' follow-up were 48.5% ± 38.6 and 15.3% ± 10.6, respectively (n = 67). Improved quality of life was observed following ESG. CONCLUSIONS: ESG is safe and effective, thus offering a satisfactory therapeutic option for a wide range of obese patients on a large scale.
- MeSH
- dospělí MeSH
- gastroplastika * metody škodlivé účinky MeSH
- gastroskopie metody MeSH
- hmotnostní úbytek MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- morbidní obezita chirurgie MeSH
- obezita chirurgie komplikace MeSH
- pooperační komplikace MeSH
- postmarketingový dozor * MeSH
- prospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
Nádory močového měchýře představují celosvětově časté onemocnění. Mnohdy se jedná o recidivující nádory s nutností dlouhodobého sledování, což z nich činí nádory s vysokou prevalencí. Základní diagnostickou metodou je cystoskopie, která je nezbytná i v rámci sledování. V obou případech, v diagnostice i dispenzarizaci, tedy využíváme invazivní metodu s nezanedbatelným rizikem komplikací. Jediným doporučeným neinvazivním vyšetřením je cytologie moči. Limitace cystoskopie a cytologie moči motivují výzkum celé řady neinvazivních biomarkerů detekovaných v moči s cílem nalezení dostatečně senzitivního a specifického vyšetření, které by bylo možné využít nejen v diagnostice a sledování nádorů močového měchýře. Doposud bylo na trh uvedeno několik biomarkerů vyskytujících se v přítomnosti nádorového postižení močového měchýře. V článku jsou představeni hlavní zástupci neinvazivních biomarkerů a jejich možné využití.
Major statement: Non-invasive urinary biomarkers represent a promising alternative to cur- rent diagnostic methods for bladder cancer. This study aims to present the main available biomarkers, evaluate their benefits, and assess their potential use in diagnosis and patient monitoring.Summary: Bladder tumors are a common disease worldwide. They are often recurrent tumors requiring long-term monitoring, making them highly prevalent. The primary diagnostic method is cystoscopy, which is also essential for follow-up. In both cases - diagnosis and surveillance - an invasive method is used, carrying a significant risk of complications. The only recommended non-invasive examination is urine cytology. The limitations of cystoscopy and urine cytology drive research into various non-invasive urinary biomarkers to find a test that is sufficiently sensitive and specific for use not only in diagnosing but also in monitoring bladder tumors. Several biomarkers associated with bladder cancer have already been introduced to the market. This article presents the main representatives of non-invasive biomarkers and their potential applications.
Rhabdomyosarcoma is a highly malignant mesenchymal tumor growing out of the primitive mesenchyme, which is (usually) differentiated into predominantly striated skeletal muscle. It is the most common soft tissue sarcoma in childhood, with a predilection site that occurs in the head and neck area. Multimodal approaches in treatment include surgery, chemotherapy, and radiotherapy. We present a case of a 6-year- old girl with a history of nasal obstruction and mucus secretion more on the left side, with loss of smell and headache above the left eye. Through clinical examination, a pink tumor was detected in the left nasal cavity. CT and MRI were complemented and showed a tumor mass filling the entire nasopharynx, propagated into the left sphenoid cavity, to the clivus, and to the prevertebral space; the tumor mass completely obturated both choanae. The patient underwent endoscopic endonasal resection of the skull base tumor using CT navigation. Embryonal rhabdomyosarcoma has been confirmed. In the postoperative period, the patient underwent adjuvant oncology treatment, and control biopsies at 2 and 16 months after surgery were negative. The patient is now three years after surgery - clinically free of signs of tumor recurrence. Conclusion: Rhabdomyosarcoma, like other tumors in the skull base region, is a challenge for the surgeon due to the location in which complete resection of the tumor is sometimes very difficult or impossible. Meticulous preoperative analysis of imaging examinations, as well as intraoperative use of CT/MRI navigation, make this possible. Complete removal of the tumor increases the patient‘s chance for successful treatmet.
Rhabdomyosarkóm je vysoko malígny mezenchymálny nádor, ktorý vyrastá z primitívneho mezenchýmu, ktorý sa normálne diferencuje prevažne na priečne pruhované kostrové svalstvo. Ide o najčastejší mäkkotkanivový sarkóm v detskom veku s preferovaným výskytom v oblasti hlavy a krku. Multimodálny prístup v liečbe zahŕňa chirurgiu, chemoterapiu a rádioterapiu. Predstavujeme prípad 6-ročného dievčaťa s anamnézou nosovej obštrukcie a hlienovej sekrécie viac na ľavej strane, so stratou čuchu a bolesťou hlavy nad ľavým okom. Pri klinickom vyšetrení bol zistený ružový nádor v ľavej nosovej dutine. Doplnené boli CT a MR vyšetrenia, ktoré ukázali nádorovú masu vypĺňajúcu celý nosohltan, s expanziou do ľavej klinovej dutiny, ku klivu a do prevertebrálneho priestoru. Nádorová masa kompletne uzatvárala obe choány. Pacientka podstúpila endoskopickú endonazálnu resekciu nádoru v oblasti prednej bázy lebky s využitím CT navigácie. Bol potvrdený embryonálny rhabdomyosarkóm. V pooperačnom období pacientka podstúpila adjuvantnú onkologickú liečbu, kontrolné bio psie 2 a 16 mesiacov po operácii boli negatívne. Pacientka je momentálne 3 roky po operácii – klinicky bez známok recidívy nádoru. Záver: Rhabdomyosarkóm, podobne ako iné nádory v oblasti prednej bázy lebky, predstavuje výzvu pre chirurga vzhľadom na lokalizáciu, v ktorej je úplná resekcia nádoru niekedy veľmi náročná alebo nemožná. Dôkladná predoperačná analýza zobrazovacích vyšetrení ako aj intraoperačné využitie CT/MR navigácie to umožňujú. Kompletné odstránenie nádoru zvyšuje šancu pacienta na úspešnú liečbu.
- MeSH
- dítě MeSH
- embryonální rhabdomyosarkom * chirurgie diagnostické zobrazování diagnóza farmakoterapie MeSH
- endoskopie metody MeSH
- lidé MeSH
- nádory hlavy a krku diagnostické zobrazování diagnóza klasifikace MeSH
- nosní obstrukce etiologie MeSH
- rhabdomyosarkom chirurgie diagnostické zobrazování diagnóza farmakoterapie MeSH
- zadní jáma lební * chirurgie patologie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
The objective of this study is to undertake a narrative review of the oncological adequacy of mediastinal lymphadenectomy performed via robot-assisted thoracic surgery (RATS) in comparison with video-assisted thoracic surgery (VATS) and thoracotomy for non-small cell lung cancer (NSCLC). The focus of the review is on lymph node yield, nodal station dissection, and nodal upstaging rates. A narrative review of literature published in the last decade was conducted using PubMed, Cochrane, and Web of Science databases. Studies examining mediastinal lymphadenectomy outcomes for RATS, VATS, or thoracotomy were included in the discussion. The analysis of 19 studies from diverse geographical regions showed that in six out of nine comparative studies, RATS demonstrated superior lymph node retrieval compared to VATS, with statistically significant differences. RATS achieved comparable or superior nodal station dissection rates and showed particular advantages in upstaging from clinical N0 to pathological N2 status. Additionally, RATS demonstrated favourable perioperative outcomes with reduced morbidity and mortality rates compared to conventional approaches. RATS represents a reliable and oncologically sound approach to mediastinal lymphadenectomy, with potential advantages over conventional techniques. Its enhanced visualization and precision make it an increasingly utilised option for NSCLC treatment in centres with robotic capabilities.
- MeSH
- hrudní chirurgie video-asistovaná metody MeSH
- lidé MeSH
- lymfadenektomie * metody MeSH
- mediastinum chirurgie MeSH
- nádory plic * chirurgie patologie MeSH
- nemalobuněčný karcinom plic * chirurgie patologie MeSH
- roboticky asistované výkony * metody MeSH
- torakotomie metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE: The authors evaluated a cohort of 12 patients with histologically verified pigmented villonodular synovitis of the TMJ between 2018 and 2023. METHODS: The authors evaluated 12 patients (12 women). Only unilateral involvement was present in all patients. The mean age of the patients was 49.5 years. The authors focused on the evaluation of clinical symptoms, imaging findings, and arthroscopic findings. They also evaluated the effect of therapy, including the incidence of recurrence. The evaluation of therapy was performed at a minimum of 12 months after therapy and a maximum of 4.5 years after therapy. RESULTS: Pain was the predominant clinical symptom (12 patients, 100%). Therapy consisted of arthroscopy and open surgery. Radiographs were taken in all patients. In 5 patients (42%) the joint structures were without obvious pathological changes, in 7 patients (58%) there was a finding of irregularities on the joint head. Magnetic resonance imaging was performed in all patients, and in 10 cases (83%) there was a finding of joint space enlargement, effusion. Therapy consisted of TMJ arthroscopy with removal of pathological tissue. If the joint was completely filled with pathological tissue, after histological verification, open surgery with complete removal of joint structures and subsequent reconstruction of the TMJ was indicated. Recurrence of PVNS was not reported in the cohort. CONCLUSION: PVNS is an uncommon benign lesion affecting the TMJ. In the authors' study, pain was the predominant symptom and effusion was the predominant finding on magnetic resonance imaging. Long-term follow-up is appropriate in patients with proven PVNS. This is due to the risk of recurrence, which is also associated with the difficulty of complete repair of the lesion in the anatomically limited space of the TMJ. The authors recommend 1,3,6 months after surgery, and annually for the first 5 years after surgery. One, two, and five years after surgery, they recommend a follow-up MRI. The results of the study support the view that MRI should always be indicated in patients with pain of arthrogenic origin lasting more than 3 months, and if effusion is found, arthroscopy should always be the next step. This procedure will ensure early detection of PVNS.
- MeSH
- artroskopie MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- nemoci temporomandibulárního kloubu * chirurgie diagnostické zobrazování patologie MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- synovitida pigmentová vilonodulární * chirurgie diagnostické zobrazování patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: This was a single-center pilot study that sought to describe an innovative use of 4DryField® PH (premix) for preventing the recurrence of intrauterine adhesions (IUAs) after hysteroscopic adhesiolysis in patients with Asherman's syndrome (AS). MATERIAL AND METHODS: Twenty-three patients with AS were enrolled and 20 were randomized (1:1 ratio) to intrauterine application of 4DryField® PH (n = 10) or Hyalobarrier® gel (n = 10) in a single-blind manner. We evaluated IUAs (American Fertility Society [AFS] score) during initial hysteroscopy and second-look hysteroscopy one month later. Patients completed a follow-up symptoms questionnaire three and reproductive outcomes questionnaire six months later. RESULTS: The demographic and clinical characteristics, as well as severity of IUAs, were comparable in both groups. The mean initial AFS score was 9 and 8.5 in the 4DryField® PH and Hyalobarrier® gel groups, respectively (p = .476). There were no between-group differences in AFS progress (5.9 vs. 5.6, p = .675), need for secondary adhesiolysis (7 vs. 7 patients, p = 1), and the follow-up outcomes. CONCLUSION: 4DryField® PH could be a promising antiadhesive agent for preventing the recurrence of IUAs, showing similar effectiveness and safety to Hyalobarrier® gel. Our findings warrant prospective validation in a larger clinical trial. CLINICAL TRIAL REGISTRY NUMBER: ISRCTN15630617.
- MeSH
- adheze tkání prevence a kontrola MeSH
- dospělí MeSH
- gely * MeSH
- gynatrézie prevence a kontrola MeSH
- hysteroskopie * metody MeSH
- jednoduchá slepá metoda MeSH
- kyselina hyaluronová aplikace a dávkování MeSH
- lidé MeSH
- nemoci dělohy prevence a kontrola chirurgie MeSH
- pilotní projekty MeSH
- recidiva MeSH
- sekundární prevence metody MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
